Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
PHOENIX, May 31, 2017 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Saeed Motahari, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the following healthcare conferences in June:
| Conference: | Jefferies 2017 Global Healthcare Conference | |||
| Date: | Thursday, June 8, 2017 | |||
| Time: | 11:00 a.m. Eastern Daylight Time | |||
| Location: | Grand Hyatt New York | |||
| Webcast: | http://wsw.com/webcast/jeff105/insy | |||
| Conference: | The JMP Securities Life Sciences Conference | |||
| Date: | Wednesday, June 21, 2017 | |||
| Time: | 12:30 p.m. Eastern Daylight Time | |||
| Panel Discussion: | Opioids | |||
| Location: | The St. Regis New York | |||
| Webcast: | Please note that JMP Securities will not webcast panel discussions. |
The Jefferies presentation will be webcast live at the aforementioned time as well as archived for 90 days thereafter, via the Company’s website at www.insysrx.com, under the Investors Section.
About INSYS
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets one product, SUBSYS® (fentanyl sublingual spray), CII, and has received approval for the marketing of SYNDROS™ (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol that INSYS believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Contact: Lisa M. Wilson T: 212-452-2793 E: [email protected]
